SEHK:3696Life Sciences
InSilico Ribo Oligonucleotide Alliance Tests AI Drug Discovery Model
InSilico Medicine Cayman TopCo (SEHK:3696) announced a new collaboration with Suzhou Ribo Life Science focused on AI-driven oligonucleotide drug development.
The partnership combines InSilico's automation and AI platforms with Ribo's expertise in oligonucleotide therapies across the drug discovery and R&D pipeline.
The companies aim to apply AI tools to target identification, molecule design, and preclinical work to support future oligonucleotide candidates.
For investors tracking...